This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock

This study has been completed.
Eli Lilly and Company
Information provided by:
Policlinico Hospital Identifier:
First received: September 7, 2005
Last updated: November 26, 2013
Last verified: February 2009
The purpose of this study is to determine the effect of the intensive insulin therapy on coagulation and fibrinolysis in patients affected by severe sepsis and septic shock. As a secondary endpoints the investigators will determine the effect of intensive insulin therapy on organ dysfunction and mortality of these patients.

Condition Intervention Phase
Severe Sepsis Septic Shock Procedure: intensive insulin therapy Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock

Resource links provided by NLM:

Further study details as provided by Policlinico Hospital:

Primary Outcome Measures:
  • The primary end-point is the evaluation of the activation/deactivation of the fibrinolytic system in the two randomization group [ Time Frame: At Baseline and every 24 hour ]

Secondary Outcome Measures:
  • To evaluate the different organ dysfunctions (pulmonary, hepatic and volemic status) [ Time Frame: 28 days survival ]
  • The effect of the treatment [ Time Frame: 28 days survival ]

Enrollment: 90
Study Start Date: November 2004
Study Completion Date: November 2007
Primary Completion Date: March 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1 Procedure: intensive insulin therapy

control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.

treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL

  Show Detailed Description


Ages Eligible for Study:   16 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Patients with sepsis, severe sepsis and sepsis shock defined as follows:


Systemic response to infection with two or more of the following conditions:

  • Body temperature<36° or >38°
  • Heart rate >90 bpm
  • Respiratory rate >20 bpm or PaCO2<32 torr
  • White cells count>12000 mm3 or <4000 mm3 or a differential count showing>10% of immature neutrophiles

Severe sepsis:

  • Sepsis associated to a organ dysfunction.

Sepsis shock:

  • Sepsis associated to hypotension despite adequate fluid resuscitation, with hypoperfusion including lactic acidosis, oliguria and acute alteration of consciousness. The hypotension does not need to be present in patients treated with inotropic or vasoactive drugs.

Exclusion Criteria:

  • Age below 16 years
  • Patients with hematologic malignancy or bone marrow transplant
  • Patients with type I diabetes
  • Patients with expected early death because of underlying disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00159952

Hospital "S.Paolo"
Milan, Italy
Policlinico Hospital
Milan, Italy
Hospital "S.Gerardo"
Monza, Italy
Sponsors and Collaborators
Policlinico Hospital
Eli Lilly and Company
Principal Investigator: Luciano Gattinoni, MD Policlinico Hospital of Milan
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Luciano Gattinoni, Policlinico Hospital Identifier: NCT00159952     History of Changes
Other Study ID Numbers: 3133
Lilly F1K0020
MIUR 2004060419
Study First Received: September 7, 2005
Last Updated: November 26, 2013

Keywords provided by Policlinico Hospital:
Septic shock

Additional relevant MeSH terms:
Shock, Septic
Systemic Inflammatory Response Syndrome
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on September 19, 2017